233 related articles for article (PubMed ID: 34729658)
1. Precise pathological classification of non-small cell lung adenocarcinoma and squamous carcinoma based on an integrated platform of targeted metabolome and lipidome.
Cao P; Wu S; Guo W; Zhang Q; Gong W; Li Q; Zhang R; Dong X; Xu S; Liu Y; Shi S; Huang Y; Zhang Y
Metabolomics; 2021 Nov; 17(11):98. PubMed ID: 34729658
[TBL] [Abstract][Full Text] [Related]
2. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
3. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
4. [Identification of differentially expressed genes between lung adenocarcinoma and squamous cell carcinoma using transcriber signature analysis].
Peng S; Li X; Liu Q; Zhang Y; Zou L; Gong X; Wang M; Ma X
Nan Fang Yi Ke Da Xue Xue Bao; 2019 Jun; 39(6):641-649. PubMed ID: 31270041
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatics analysis of differentially expressed miRNAs in non-small cell lung cancer.
Yu H; Pang Z; Li G; Gu T
J Clin Lab Anal; 2021 Feb; 35(2):e23588. PubMed ID: 32965722
[TBL] [Abstract][Full Text] [Related]
6. Integrative metabolomics and transcriptomics analysis reveals novel therapeutic vulnerabilities in lung cancer.
Thaiparambil J; Dong J; Grimm SL; Perera D; Ambati CSR; Putluri V; Robertson MJ; Patel TD; Mistretta B; Gunaratne PH; Kim MP; Yustein JT; Putluri N; Coarfa C; El-Zein R
Cancer Med; 2023 Jan; 12(1):584-596. PubMed ID: 35676822
[TBL] [Abstract][Full Text] [Related]
7. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
8. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
9. Blood FOLR3 methylation dysregulations and heterogeneity in non-small lung cancer highlight its strong associations with lung squamous carcinoma.
Qu Y; Zhang X; Qiao R; Di F; Song Y; Wang J; Ji L; Zhang J; Gu W; Fang Y; Han B; Yang R; Dai L; Ouyang S
Respir Res; 2024 Jan; 25(1):59. PubMed ID: 38273401
[TBL] [Abstract][Full Text] [Related]
10. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
11. Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma.
Cao B; Wang P; Gu L; Liu J
Oncol Lett; 2021 Apr; 21(4):249. PubMed ID: 33664813
[TBL] [Abstract][Full Text] [Related]
12. Association of TOP2A and ADH1B with lipid levels and prognosis in patients with lung adenocarcinoma and squamous cell carcinoma.
Yin D; Zhang Y; Li H; Cheng L
Clin Respir J; 2023 Dec; 17(12):1301-1315. PubMed ID: 37985446
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Dong R; Liu J; Sun W; Ping W
Pathol Oncol Res; 2020 Jul; 26(3):1935-1945. PubMed ID: 31898160
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
15. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma.
Jain D; Nambirajan A; Chen G; Geisinger K; Hiroshima K; Layfield L; Minami Y; Moreira AL; Motoi N; Papotti M; Rekhtman N; Russell PA; Prince SS; Schmitt F; Yatabe Y; Eppenberger-Castori S; Bubendorf L;
J Thorac Oncol; 2022 Jun; 17(6):793-805. PubMed ID: 35331963
[TBL] [Abstract][Full Text] [Related]
16. What's the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients.
Wang W; Liu H; Li G
Front Endocrinol (Lausanne); 2022; 13():947443. PubMed ID: 36105402
[TBL] [Abstract][Full Text] [Related]
17. LINC00628 is differentially expressed between lung adenocarcinoma and squamous cell carcinoma and is associated with the prognosis of NSCLC.
Liu T; Xu S; Liu X
Oncol Lett; 2022 Feb; 23(2):55. PubMed ID: 34992687
[TBL] [Abstract][Full Text] [Related]
18. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
19. Lung adenocarcinoma and lung squamous cell carcinoma cancer classification, biomarker identification, and gene expression analysis using overlapping feature selection methods.
Chen JW; Dhahbi J
Sci Rep; 2021 Jun; 11(1):13323. PubMed ID: 34172784
[TBL] [Abstract][Full Text] [Related]
20. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
Tuna M; Mills GB; Amos CI
Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
